Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by cpacon Dec 30, 2019 1:44pm

252 Views

Post# 30502067

Ideal Scenario:

This run up is due to negotiating a licensing deal in ONE indication (breast cancer, pancreatic cancer, multiple myeloma - you take your pick) which has a LARGE up front cash component (like the Turnstone/Takeda deal). Analysts and investors get busy on extrapolating the worth of the entire company based on the value placed on licensing Pelareorep for one indication... which then sets a fair price for acquiring the company as a whole...

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025